Drug Profile
Azercabtagene zapreleucel - Precision BioSciences
Alternative Names: Allogeneic-anti-CD19-CAR-T-cells-Precision-BioSciences/Servier; anti-CD19 CAR T Cells - Precision BioSciences/Servier; anti-CD19 chimeric antigen receptor T-cell therapy - Precision BioSciences/Servier; Azer-Cel; PBCAR-0191Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Baxalta; Precision Biosciences
- Developer Precision Biosciences
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma